2 boys' deaths halt S.F. company's rare disease gene therapy trial
Two boys died in a critical gene therapy trial against a genetic disease, forcing the company behind the therapy and regulators to halt the study.
Audentes Therapeutics Inc., a San Francisco company that was sold in January to Astellas Pharma of Japan for $3 billion, said both boys with X-linked myotubular myopathy had been given a higher dose of the therapy and had pre-existing liver problems.
The news comes as gene therapies face question s as well as a pivotal moment. BioMarin Pharmaceutical…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Boys | Centronuclear Myopathies | Gene Therapy | Genetics | Health Management | Japan Health | Liver | Pharmaceuticals | Rare Diseases | Study | Urology & Nephrology